“abbvie” Archives

in
Entry Author Date Location
With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss 09/03/19 Boston
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More 08/30/19 National
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop 08/29/19 Detroit Ann Arbor
Celgene to Sell Blockbuster Drug to Amgen for $13B to Close BMS Deal 08/26/19 New York
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
New BC Biotech Chinook Reels in $65M to Tackle Kidney Disease 08/22/19 National
AbbVie’s Successor to Humira Wins FDA OK for Rheumatoid Arthritis 08/16/19 National
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More 08/16/19 National
Four New Drugs Are Around the Corner. Here’s What You Need to Know. 08/15/19 National
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More 08/02/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More 07/19/19 National
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira 06/25/19 Detroit Ann Arbor
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More 06/21/19 National
Oncternal Therapeutics Goes Public After Reverse Merger With GTx 06/12/19 San Diego
Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More 05/24/19 National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More 04/26/19 National
Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More 03/15/19 National
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away 02/26/19 National
Voyager Therapeutics, AbbVie Add Parkinson’s to Gene Therapy Pact 02/22/19 Boston
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More 02/22/19 National
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug 02/11/19 San Francisco
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials 02/06/19 San Francisco
Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M 02/06/19 San Diego
Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs 01/07/19 San Francisco
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More 01/04/19 National
Tizona Lands $105M from AbbVie in Cancer Drug R&D Alliance 01/03/19 San Francisco
Acorda Gets FDA Nod for New Parkinson’s Drug, But Rival Looms 12/24/18 New York
Gilead, Scholar Rock Sign $80M Up Front Deal for Fibrosis Drugs 12/19/18 Boston
Page 1 of 6 next page »